These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 22551107)

  • 1. Combination chemotherapy in advanced adrenocortical carcinoma.
    Fassnacht M; Terzolo M; Allolio B; Baudin E; Haak H; Berruti A; Welin S; Schade-Brittinger C; Lacroix A; Jarzab B; Sorbye H; Torpy DJ; Stepan V; Schteingart DE; Arlt W; Kroiss M; Leboulleux S; Sperone P; Sundin A; Hermsen I; Hahner S; Willenberg HS; Tabarin A; Quinkler M; de la Fouchardière C; Schlumberger M; Mantero F; Weismann D; Beuschlein F; Gelderblom H; Wilmink H; Sender M; Edgerly M; Kenn W; Fojo T; Müller HH; Skogseid B;
    N Engl J Med; 2012 Jun; 366(23):2189-97. PubMed ID: 22551107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
    Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
    Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
    Uchihara M; Tanioka M; Kojima Y; Nishikawa T; Sudo K; Shimoi T; Noguchi E; Maeshima AM; Yonemori K
    Int J Clin Oncol; 2021 Dec; 26(12):2275-2281. PubMed ID: 34468885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
    Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
    Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
    J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Three Cases of Advanced or Recurrent Adrenocortical Carcinoma Patients Treated with Etoposide, Doxorubicin and Cisplatin plus Mitotane].
    Sasaki S
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):67-70. PubMed ID: 29362311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenocortical carcinoma.
    van Ditzhuijsen CI; van de Weijer R; Haak HR
    Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
    Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C
    Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study.
    Debets P; Dreijerink KMA; Engelsman A; Dahele M; Haak HR; Steenaard RV; Kapiteijn E; Corssmit E; Menke-van der Houven van Oordt CW
    Eur J Cancer; 2024 Jan; 196():113424. PubMed ID: 37977106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
    Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
    Laganà M; Grisanti S; Ambrosini R; Cosentini D; Abate A; Zamparini M; Ferrari VD; Gianoncelli A; Turla A; Canu L; Terzolo M; Tiberio GAM; Sigala S; Berruti A
    ESMO Open; 2022 Apr; 7(2):100422. PubMed ID: 35272132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer.
    Roca E; Berruti A; Sbiera S; Rapa I; Oneda E; Sperone P; Ronchi CL; Ferrari L; Grisanti S; Germano A; Zaggia B; Scagliotti GV; Fassnacht M; Volante M; Terzolo M; Papotti M
    Endocr Relat Cancer; 2017 Jul; 24(7):319-327. PubMed ID: 28432084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
    Lerario AM; Worden FP; Ramm CA; Hesseltine EA; Stadler WM; Else T; Shah MH; Agamah E; Rao K; Hammer GD
    Horm Cancer; 2014 Aug; 5(4):232-9. PubMed ID: 24849545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
    Boilève A; Mathy E; Roux C; Faron M; Hadoux J; Tselikas L; Al Ghuzlan A; Hescot S; Leboulleux S; de Baere T; Lamartina L; Deschamps F; Baudin E
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4698-e4707. PubMed ID: 34143888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
    Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
    Ueda S; Nakane K; Namiki S; Takeuchi Y; Kawase M; Takeuchi S; Kawase K; Nakai C; Kato D; Takai M; Iinuma K; Tsuchiya T; Miyazaki T; Koie T
    Hinyokika Kiyo; 2022 May; 68(5):139-143. PubMed ID: 35748231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma.
    Cosentini D; Turla A; Carminati O; Grisanti S; Ferrari VD; Laganà M; Rosti G; Sigala S; Berruti A
    Front Endocrinol (Lausanne); 2021; 12():674039. PubMed ID: 33967965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.
    Khan TS; Imam H; Juhlin C; Skogseid B; Gröndal S; Tibblin S; Wilander E; Oberg K; Eriksson B
    Ann Oncol; 2000 Oct; 11(10):1281-7. PubMed ID: 11106117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.